Breast Cancer Updates
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Clinical Considerations of Neoadjuvant Endocrine Therapy in Breast Cancer: Downsizing Tumors for Improved Surgical Outcomes & Identification of HR+ BCs That Don’t Require CT
FEATURING
Vandana Abramson
- 259 views
- February 26, 2020
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
How Should We Be Taking Advantage of Neoadjuvant Endocrine Therapy? ER+ MBC: Where Do We Stand Today in Terms of PFS and OS? Key Differences Among the 3 CDK4/6
FEATURING
Vandana Abramson
- 411 views
- February 26, 2020
- 1
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Optimal Approach to Residual HR+ and HER2+ Breast Cancer
FEATURING
Heather McArthur
- 280 views
- February 27, 2020
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Clinical Trials of Immune Checkpoint Inhibitors in Early Stage Breast Cancer: Neoadjuvant Durvalumab, Neoadjuvant Pembrolizumab, Pembro 8-no AC, Chemo + Pembro, & Atezolizumab with Neoadjuvant Chemo
FEATURING
Rita Nanda
- 877 views
- February 27, 2020
- 1